NEW YORK, May 2, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sunesis Pharmaceuticals, Inc. ("Sunesis" or the "Company") (NASDAQ: SNSS). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/snss.
The investigation concerns whether Sunesis and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On May 2, 2017, Sunesis announced that it will withdraw its European Marketing Authorization Application for vosaroxin, its proposed treatment for relapsed/refractory AML. Sunesis conveyed to shareholders that its decision followed recent interactions with the European Medicine Agency's Committee for Medicinal Products for Human Use, in which it learned that the committee was likely to formally adopt a negative opinion in its evaluation of the product. Following this news, Sunesis stock dropped as much as $0.81 per share, or 22.13%, during intraday trading on May 2, 2017.
If you are aware of any facts relating to this investigation, or purchased shares of Sunesis, you can assist this investigation by visiting the firm's site: www.bgandg.com/snss. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-sunesis-pharmaceuticals-inc-snss-300449902.html
SOURCE Bronstein, Gewirtz & Grossman, LLC